AZD4604 in Asthma - Clinical Trials Registry - ICH GCP A Phase 2a Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult . . . A Phase 2a Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
AJAX - Health Research Authority So, researchers think AZD4604 could help people with asthma that is not controlled well enough by currently available inhaled treatments This is a Phase 2, randomized, double-blind, placebo-controlled trial
AJAX Study: New Inhaled Medication for Uncontrolled Asthma Participants must have a diagnosis of asthma and be taking a medium or high dose of inhaled corticosteroids with a long-acting bronchodilator medication (such as Symbicort®, ADVAIR®, Breo Ellipta®, Wixela®, Dulera®) for at least the past 3 months
Asthma Clinical Trial - AJAX The purpose of this study to Assess Efficacy and Safety of Multiple Dose Levels of AZD5718 Given Orally Once Daily for Twelve Weeks in Adults with Moderate-to-Severe Uncontrolled Asthma
Asthma - Moderate to Severe - (AJAX Study) - CCHC Healthcare Coastal Carolina Health Care, P A (CCHC) is participating in a clinical trial for OSA at our Pulmonary and Sleep Medicine office You may qualify for this study if you: Have been diagnosed with Asthma prior to study enrollment
AJAX Study - Support the Next Wave of Asthma Treatment Research AJAX is a new clinical study for people with asthma We are looking at whether an experimental treatment called AZD4606 may improve asthma symptoms and help reduce the risk of flare-ups AZD4604 is taken using an inhaler, like other asthma medicines Those who qualify may receive: Study-related treatment at no cost
AZD4604, An Inhaled, Selective JAK1 Inhibitor Reduces Fractional . . . AZD4604 caused rapid FeNO reduction in patients with mild asthma, at dose levels that were well tolerated and with minimal systemic TE Further research is required to determine the clinical benefit and safety in more severe asthma populations receiving current standard of care
Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation . . . The purpose of this study is to investigate the effect on airway inflammation and JAK1-associated signalling pathways of AZD4604 compared with placebo in participants with moderate-to-severe asthma Study details include: - The study duration for each participant will be approximately 10 weeks
Asthma - Ajax ON (Clinical Trial # 325550) Individuals on a daily asthma medication and rescue inhaler may be eligible for a clinical trial Researchers are seeking participants who have had a flare-up in the past year, and travel reimbursement may be available